1/7/2024 0 Comments Blueprint geneThe agent also demonstrated a promising safety profile, with 96.5% of patients in the avapritinb arm completing treatment at 24 weeks vs 93.0% in the control arm. Additional findings showed that serum tryptase reduction of 50% or more was achieved by 53.9% of patient in the experimental arm experiencing compared with no patients in the control arm. In the control group, the mean TSS reduction was 9.2 points at 24 weeks. 003) with a mean reduction of 15.6 points which increased to 20.2 points at 48 weeks among those who rolled over to the phase 3 expansion study. The disease is known to result in skin, gastrointestinal, neurocognitive, and other systemic symptoms as well as potential fatal anaphylaxis.įindings from the study indicated that the primary end point of significant mean change in total symptom score (TSS) at 24 weeks with the experimental regimen was met ( P =. ”Īvapritinb is a selective inhibitor of D816V mutant KIT, a known driver of systemic mastocytosis for 95% of reported cases. The trial results suggest that if approved, Ayvakit would represent a practice-changing treatment, enabling important clinical benefits for a broad range of patients with non-advanced. “For patients with non-advanced, PIONEER is the first study to show significant clinical improvements over best available care across patient-reported symptoms and objective measures of disease, with a safety and tolerability profile supporting chronic treatment. “As a physician and clinical researcher who has been treating non-advanced systemic mastocytosis for over 25 years, I have been awaiting a therapy that decreases the abnormal mast cell burden and activation, improves a wide range of symptoms, and ultimately provides an improved quality of life to patients,” investigator Mariana Castells, MD, PhD, director of the Mastocytosis Center at Brigham and Women’s Hospital, said in the press release.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |